Tactile Systems Technology Inc (Tactile Medical) is a medical technology company that develops and provides medical devices for the treatment of underserved chronic diseases. The company focuses on advancing the standard of care in treating vascular disease, oncology, and chronic respiratory conditions. The company offers a range of products and services primarily focused on treating lymphedema and chronic venous insufficiency. Their proprietary systems include the Flexitouch, Entre, and Nimbl systems.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Tactile Medical's R&D arm focuses on engineering, scientific, and clinical research in therapies for treating lymphedema, cancer-related lymphedema, chronic venous insufficiency, bronchiectasis, and other chronic respiratory conditions. The company's expertise includes pneumatics, electronics, garment design, embedded software, mechanical design, sensors, manufacturing technologies, and clinical trial management. Current efforts are directed towards improving design for ease-of-use, reducing production costs, and differentiating products from competitors. Development efforts are coordinated with external advisors and intellectual property strategies to enhance patent and intellectual property protection. The R&D unit of Tactile Medical are responsible for coordinating development efforts with external advisors and managing intellectual property strategies to enhance the company's ability to obtain patent and other intellectual property protection. In FY2025, the company spent US$8.4 million on its R&D activities, which as a percentage of revenue stood at 2.5% and grew 12.5% YoY. As of December 2025, the company owned 172 issued patents globally, including 61 issued US patents. It also consists of 21 pending patent applications, of which ten are pending patent applications in the US. It owns US patents from 2026 to 2040.